Background/Objectives: Atopic dermatitis (AD) is a chronic condition that is pre-
antimicrobial environment. Mainstay therapies for AD include topical corticosteroids (TCS) in addition to nonpharmaceutical therapies such as moisturizers, bathing techniques, and wet wrap therapy (WWT).
Topical calcineurin inhibitors (TCI), topical antihistamines and antipruritics, and topical antimicrobials are added as adjunctive therapies. In severe and refractory cases, systemic immunosuppressive and targeted immunomodulating agents are warranted. There are a number of AD treatment guidelines internationally, and the goal of this review was to discuss and compare AD treatment recommendations across international guidelines.
| ME TH ODS
A thorough literature search was conducted in May 2018 using PubMed, EMBASE, and MEDLINE for published guidelines in each geographic region. Search terms used included "atopic dermatitis," "clinical practice guideline," and "treatment." Abstracts were reviewed, and literature was included if it was available in English, included the most recently published guidelines, was published between 2007 and 2018, was established by an association that includes dermatologists, pertained to the treatment of AD in humans, and included comprehensive treatment recommendations.
When more than one guideline was published for a given country, the most comprehensive one was chosen. Publications were omitted if unavailable in English, pertained to AD treatment for animals, focused on only one treatment modality, or was established by a nondermatologic society or a group without dermatologists.
| RESULTS
Guidelines fitting inclusion and exclusion search criteria were selected from 12 independent countries and 2 organizations (the European Academy of Dermatology and Venereology and the Japanese Dermatological Association). Table 1 contains a list of selected published guidelines discussed in this review.
Articles selected for this review amounted to 14 different guidelines across 19 publications (some guidelines were published in several parts). Selected publications were created by dermatological associations, appointed task forces, and committees composed of mostly dermatological experts in AD. Guidelines from Central American, South America, and most of the Asian and African countries were not identified.
| Moisturizers
Moisturizer use, even on nonlesional skin, is mutually agreed upon and recommended by all guidelines. Most guidelines recommend applying large quantities of moisturizer 2 to 3 times a day, although differences exist regarding the recommended dose for adult and pediatric patients. The Polish, Singaporean, and European guidelines are the only three that warn against certain compounds in moisturizers, such as urea, sodium chloride, and propylene glycol. [3] [4] [5] Additionally, the Polish and Italian guidelines are the only ones that recommend specific ingredients such as petrolatum, ceramides, and glycerol. 3, 6 The European guidelines discuss the benefit of emollients "plus," which contain active ingredients that do not qualify as a topical drug. These include saponins, flavonoids, and riboflavin from protein-free oat plantlet extracts, and Aquaphilus dolomiae or Vitreoscilla filiformis bacterial lysates. Wallenberg et al. cite studies demonstrating that lysates decrease AD lesion severity but do not make any official recommendations for their use. 5 Table 2 includes a summary of the international guidelines for moisturizer use in AD.
| Bathing
Bathing is crucial for skin hygiene, and although water is an immediate means of hydrating the skin, it can act as a drying agent if left to evaporate. Therefore, postbath moisturizer use, the so-called soakand-smear practice, is generally recommended to reduce this drying effect. 7 Across international guidelines, skin cleansing is viewed as vital toward maintaining skin barrier function and reducing rates of infection. Among the guidelines that recommend bathing frequency/duration, very little variation exists. A bath duration of 5-10 minutes once daily is generally recommended; however, the European guidelines recommend only a short duration (5 minutes) with the use of bath oils (commercially available in Europe) in the last 2 minutes of bathing. 5 Because conventional soaps strip the skin's natural oil and alkalize stratum corneum (SC) pH, the use of nonsoap, nonirritant, hypoallergenic, and neutral pH cleansers is generally recommended.
The U.S., Korean, and Italian guidelines specifically recommend the use of synthetic syndets as nonsoap alternatives. [6] [7] [8] Differences also exist regarding bath additive recommendations. Bleach baths are reviewed in the antimicrobials section. Table 3 includes a summary of the international guidelines for bathing in AD.
| Wet wrap therapy
Wet wrap therapy can be implemented for recalcitrant AD and flares. First, a moisturizer or antiinflammatory medication (eg, TCS or TCI) is applied to the skin, followed by a damp tubular bandage or gauze, and then a dry tubular bandage wrapped on the exterior. 7 Form-fitting cotton pajamas can be used instead of a tubular bandage for a more convenient application. 9 The U.S. guidelines recommend the wrap be worn for several hours (up to 24) depending on the patient's tolerance. 7 The British, Italian, European, and Polish guidelines state that daily WWT with TCS application should be limited to 14 days, whereas the Singaporean guidelines recommend limiting it to 7 days. [3] [4] [5] [6] 10 Only the South African guidelines recommend against WWT, citing both a lack of studies demonstrating additional benefit and a lack of studies conducted in South Africa. 11 Each supporting guideline warns against possible increase in TCS absorption with WWT. Limiting the amount of time that wraps are applied and monitoring for systemic side
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| Topical corticosteroids
All guidelines discuss the importance of considering the patient's age, disease severity, and location when prescribing TCS. This is especially crucial in children, given their higher body surface-toweight ratio and subsequent increased risk of systemic absorption. be treated with mid-to-high-potency TCS over short periods. 12 However, Singaporean guidelines recommend that the lowest therapeutic potency should be used and that high-potency TCS should be avoided in children under 12 months of age. 4 Although TCS use and the concept of the fingertip unit (FTU; approximately 0.5 g of topical agent) are recommended across international guidelines, there is a scarcity of evidence to support an optimal dosage, and a variety of recommendations exist. 7 Asia-Pacific, Italian, and European guidelines include specific dosage recommendations for different ages, whereas other guidelines have no dosage recommendations. 5, 6, 13 Most guidelines also recommend once-or twice-daily application to control flares and recognize clinical evidence supporting that once daily may be sufficient.
14 Topical corticosteroids are commonly used as maintenance therapy to reduce the incidence of flares. Nearly all guidelines recommend "weekend therapy on hot spots," defined as application of TCS twice weekly to a previous flare spot despite absence of lesions.
The risk of potential side effects has contributed to "steroid phobia," Moisturizer with a hydrophilic base (ie, 5% urea).
Not mentioned
Emollients with a higher lipid content are preferable in the wintertime.
a widespread phenomenon that can result in decreased compliance and misuse. 3 Most guidelines discuss this concept and stress patient education to ensure proper TCS administration and use. Table 5 includes a summary of the international guidelines for TCS use in AD.
| Topical calcineurin inhibitors
Guidelines universally recommend TCI for AD refractory to TCS, requiring chronic TCS, or involving sensitive skin. 15 A number of guidelines recommend both topical tacrolimus and pimecrolimus as second-line therapies, whereas Singaporean, German, and Polish guidelines recommend these medications as first line in areas prone to skin atrophy from TCS, termed "problem areas." 3, 4, 16 Compared to topical steroids, there is a lack of recommendations for TCI dose and frequency. The U.S., U.K., South African, Tai Table 6 includes a summary of the international guidelines for TCI use in AD.
| Topical antihistamines and antipruritics
All guidelines either recommend against or do not mention topical antihistamines. The U.S., Italian, European, Taiwanese, and German guidelines recommend against topical antihistamines due to potential side effects, such as application site irritation and possible allergic reaction. [5] [6] [7] 16, 17 There are a wide range of antipruritic therapies, including topical anesthetics, topical cannabinoid receptor agonists, topical capsaicin, topical mast cell stabilizers, N-acetylcysteine, oils, coal tar products, polidocanol, tannins, zinc, and sodium cromoglycate. Most guidelines either recommend against or do not mention these therapies. The
German, Polish, and Serbian guidelines recommend other antipruritic agents such as shale oils, tannins, and crisaborole, respectively. 3, 16, 20 The European guideline recommends the use of TCI, TCS, and the anesthetic polidocanol to reduce pruritus. 5 Almost all guidelines recommend avoidance of environmental irritants such as sweat or stiff clothing such as wool. 
| Systemic antihistamines and antipruritics
Most guidelines recommend sedating, first-generation oral antihistamines (SOAs) when AD causes sleep disturbance. However, the German, European, and Japanese guidelines recommend against the use of SOAs (even in the setting of itch) due to their unfavorable risk-benefit profile.
5,16,18
Most Asian and the U.S. guidelines recommend nonsedating oral antihistamines (NOAs) if patients have concomitant urticaria. 4, 13, 17, 23, 24 Further, a number of guidelines recommend against the use of NOAs in the absence of urticaria or allergic rhinitis. Evidence that NOAs improve pruritus in AD in the absence of urticaria is lacking. Interestingly, the Serbian guidelines recommend tofacitinib as an antipruritic therapy. 20 The European guidelines also discuss the use of opioid receptor antagonists (ie, naltrexone and nalmefene) and SSRIs to treat pruritus but recommend neither for routine treatment. 5 Table 9 includes a summary of the international guidelines for antihistamine and antipruritic use in AD.
| Systemic antimicrobials
All except the Serbian guidelines either recommend against or do not mention continuous long-term oral antibiotics for AD. 20 The Serbian guidelines recommend the use of oral antimicrobials in the setting of flares. 20 The other guidelines recommend short-term oral antibiotics only in cases of overt infection. All guidelines either recommend against or do not mention the use of oral antivirals unless there are clinical signs of eczema herpeticum, coxsackium, or molluscum contagiosum infection. Several guidelines recommend antifungal treatment in cases of "head and neck" dermatitis from Malassezia infection, colonization, and hypersensitivity. 3, 6, 16, 20, 22, 24 Several guidelines also recommend obtaining a culture when infection is recurrent or resistant to treatment. Table 10 includes a summary of the international guidelines for systemic antimicrobial use in AD.
| Systemic immunomodulators
Systemic corticosteroids and other immunomodulating agents are used for moderate-to-severe AD that is refractory to phototherapy and all other topical therapies, or when the quality of life has diminished to an unsatisfactory level. 25 Of note, most of the guidelines do not provide recommendations for specific tapering timelines or directions for how to safely use more than one systemic at a time.
| Oral corticosteroids
The U.S. and Singaporean guidelines state that short-term OCS use can be considered for severe exacerbations while another modality (systemic or phototherapy) is being initiated. 4 Otherwise, the use of OCS should be avoided in both adult and pediatric patients. 23 The remainder of the guidelines are unanimous in recommending OCS avoidance except in severe exacerbations (Table 11 ).
| Cyclosporine
All guidelines recommend cyclosporine when AD is refractory to first-and second-line therapies. Severe potential side effects exist, as do drug interactions with medications such as statins, certain antibiotics, antifungals, antiepileptics, and HIV protease inhibitors. 26 Therefore, caution should be exercised when prescribing cyclosporine to patients, and short-term therapy is recommended. 27 Dosage and frequency recommendations are similar (3-5 mg/kg/d) between those that provide them. Exact dosage, frequency, and duration recommendations are listed in Table 12 .
| Azathioprine
Azathioprine is recommended as a second-line therapy by several guidelines, but only to be used after cyclosporine fails to achieve symptom relief; this is due to decreased effectiveness as well as more severe side effects. 3, 4, 10, 16, 22, 24 Consensus among guidelines supports a dose of about 2.5 mg/kg/d, although no optimal dosing or therapy duration exists. 25 It is generally recommended to first determine the levels of thiopurine methyltransferase (TPMT) before deciding on dosage. 6 Exact dosage and frequency recommendations are listed in Table 12 .
| Methotrexate
Methotrexate (MTX) is commonly used off-label for AD as a second-line therapy when cyclosporine fails to provide therapeutic effects. 25 Folate supplementation during MTX administration is widely recommended. 6 All but the South African guidelines recommend MTX when symptoms are refractory to cyclosporine. 28 Generally, doses of 7. (Continues)
| Mycophenolate mofetil
Mycophenolate mofetil (MMF), similar to azathioprine and methotrexate, is used off-label to treat AD. 25 Many guidelines recommend MMF as a second-line therapy for refractory disease. 3, 11, 13, 16, 17, 19, [22] [23] [24] The
Asia-Pacific, Korean, Taiwanese, South African, German, and European guidelines recommend up to 2 g/d in adult patients. 13 ,17,21,22,24,28
| Interferon-gamma
Interferon-gamma (IFN-γ) is used off-label for the treatment of AD.
25
A few guidelines recommend exogenous IFN-γ in severe cases refractory to other systemic therapies or phototherapy. 10, 23, 24 Dosage recommendations are lacking.
| Oral calcineurin inhibitors
In the United States, tacrolimus is available in oral and intravenous (IV) forms, whereas pimecrolimus is only available topically. Oral and IV tacrolimus are used in antirejection prophylaxis, and there is insufficient evidence to support its use in the treatment of AD. 31 The U.S. guideline is the only one to mention oral calcineurin inhibitors, and it specifically recommends against their use. 
| Others
The 2018 European guideline also discusses the use of rituximab, omalizumab, ustekinumab, mast cell stabilizers, tofacitinib, leukotriene antagonists, mast cell stabilizers, apremilast, and IVIG; all of these are not recommended. Alternatively, they state that mepolizumab, alitretinoin (for hand eczema specifically), apremilast, and immunoadsorption (for severe AD with high serum IgE) may be considered when unresponsive to standard therapy. Additionally, the cost of AD treatment modalities should also be considered as updated guidelines are developed. This is especially true in developing countries where medications and products are either unavailable or too expensive. Insurance coverage also plays a major role in physicians' freedom to prescribe and should be a point of discussion. Recommendations for how to navigate the potential hurdles of cost, coverage, and availability that are region-specific will be useful for health care professionals treating patients with AD.
| CONCLUSION
This review highlights the international guideline recommendations for general maintenance, bathing, and topical and systemic therapies for AD. Due to regional and cultural differences, it may be impractical to have a standardized management protocol. Future guidelines will need to be updated to incorporate new emerging targeted therapies, such as biologics and small molecules, as they become available. 34 Lastly, because these guidelines are general recommendations, treatment should be tailored to the unique needs and tolerability of each patient.
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